Franco Buzzi

3.2k total citations · 1 hit paper
42 papers, 1.9k citations indexed

About

Franco Buzzi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Franco Buzzi has authored 42 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 9 papers in Genetics. Recurrent topics in Franco Buzzi's work include Cancer Treatment and Pharmacology (15 papers), Colorectal Cancer Treatments and Studies (12 papers) and Estrogen and related hormone effects (9 papers). Franco Buzzi is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Colorectal Cancer Treatments and Studies (12 papers) and Estrogen and related hormone effects (9 papers). Franco Buzzi collaborates with scholars based in Italy, United Kingdom and United States. Franco Buzzi's co-authors include Maurizio Tonato, B. Massidda, P Sismondi, Giancarlo Agnelli, C. Bianchini, Rodolfo Passalacqua, Melina Verso, Vito Lorusso, A. Rubagotti and Francesco Boccardo and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Franco Buzzi

42 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

2009 446 citations Giancarlo Agnelli, Gualberto Gussoni et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Franco Buzzi Italy	19	1.0k	658	555	415	412	42	1.9k
Charles Kuzma United States	11	697 0.7×	99 0.2×	518 0.9×	261 0.6×	391 0.9×	20	1.3k
Margot J. Burnell Canada	12	649 0.6×	84 0.1×	420 0.8×	254 0.6×	225 0.5×	32	1.1k
Joe Costantino United States	2	592 0.6×	545 0.8×	687 1.2×	143 0.3×	68 0.2×	3	1.2k
Paul Stonelake United Kingdom	20	433 0.4×	47 0.1×	369 0.7×	218 0.5×	330 0.8×	40	1.5k
K. Syrigos Greece	23	1.1k 1.1×	35 0.1×	288 0.5×	638 1.5×	173 0.4×	73	1.9k
J. N. Atkins United States	13	754 0.7×	149 0.2×	643 1.2×	256 0.6×	47 0.1×	24	1.2k
Raman Desikan United States	18	1.8k 1.8×	78 0.1×	171 0.3×	197 0.5×	222 0.5×	35	4.5k
Anders Själander Sweden	24	452 0.4×	65 0.1×	147 0.3×	85 0.2×	491 1.2×	81	1.9k
Emanuele Naglieri Italy	15	336 0.3×	35 0.1×	141 0.3×	200 0.5×	206 0.5×	42	1.0k
Chris Robertson Italy	13	849 0.8×	359 0.5×	1.7k 3.0×	217 0.5×	38 0.1×	17	2.4k

Countries citing papers authored by Franco Buzzi

Since Specialization

Citations

This map shows the geographic impact of Franco Buzzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franco Buzzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franco Buzzi more than expected).

Fields of papers citing papers by Franco Buzzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franco Buzzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franco Buzzi. The network helps show where Franco Buzzi may publish in the future.

Co-authorship network of co-authors of Franco Buzzi

This figure shows the co-authorship network connecting the top 25 collaborators of Franco Buzzi. A scholar is included among the top collaborators of Franco Buzzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franco Buzzi. Franco Buzzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Agnelli, Giancarlo, Gualberto Gussoni, C. Bianchini, et al.. (2009). Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. The Lancet Oncology. 10(10). 943–949. 446 indexed citations breakdown →

Boccardo, Francesco, A. Rubagotti, Pamela Guglielmini, et al.. (2006). Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Annals of Oncology. 17(7). vii10–vii14. 158 indexed citations

Comella, P., G. Frasci, B. Massidda, et al.. (2004). Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. British Journal of Cancer. 91(3). 489–497. 54 indexed citations

Cresta, Sara, Giacomo Grasselli, Mauro Mansutti, et al.. (2004). A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Annals of Oncology. 15(3). 433–439. 29 indexed citations

Mazzanti, Paola, Cristian Massacesi, Marco Rocchi, et al.. (2003). Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 41(1). 81–89. 61 indexed citations

Comella, P., A. Farris, Vito Lorusso, et al.. (2003). Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma. British Journal of Cancer. 89(6). 992–996. 17 indexed citations

Comella, P., E. Crucitta, Ferdinando De Vita, et al.. (2002). Addition of either irinotecan or methotrexate to bolus5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Annals of Oncology. 13(6). 866–873. 23 indexed citations

Mazzanti, Paola, Cristian Massacesi, Rodolfo Mattioli, et al.. (2001). Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a multicenter phase II randomized trial. European Journal of Cancer. 37. S50–S50. 7 indexed citations

Gershanovich, M., Daniel de Castro, H. Lurie, et al.. (1999). [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].. PubMed. 45(4). 361–8. 1 indexed citations

10.

Gershanovich, M., H.A. Chaudri, H. Lurie, et al.. (1998). Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Annals of Oncology. 9(6). 639–645. 206 indexed citations

11.

Cocconi, Giorgio, Mariangela Bella, F. Calabresi, et al.. (1992). Treatment of Metastatic Malignant Melanoma with Dacarbazine plus Tamoxifen. New England Journal of Medicine. 327(8). 516–523. 180 indexed citations

12.

Buzzi, Franco, et al.. (1991). Lung Cancer After Treatment of Hodgkin'S Disease—A Case Report. Acta Oncologica. 30(5). 651–652. 1 indexed citations

13.

Cocconi, Giorgio, Giancarlo Bisagni, M. Bacchi, et al.. (1990). A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Annals of Oncology. 1(1). 36–44. 18 indexed citations

14.

Crinò, Lucio, Maurizio Tonato, Samir Darwish, et al.. (1990). A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemotherapy and Pharmacology. 26(1). 52–56. 40 indexed citations

15.

Basurto, Carlo, Fausto Roila, Maurizio Tonato, et al.. (1989). Antiemetic Activity of High-Dose Metoclopramide Combined with Methylprednisolone Versus Metoclopramide Alone in Dacarbazine-Treated Cancer Patients. American Journal of Clinical Oncology. 12(3). 235–238. 19 indexed citations

16.

Colozza, Mariantonietta, Stefania Gori, Anna Maria Mosconi, et al.. (1989). Chemotherapy with cis-Platin, Doxorubicin, and Cyclophosphamide (CAP) in Patients with Metastatic Breast Cancer. American Journal of Clinical Oncology. 12(2). 137–141. 10 indexed citations

17.

Nuzzo, Fiorella, V. Tison, Ethel‐Michele de Villiers, et al.. (1988). Human Papillomavirus (HPV) Cervical Lesions: Results from 300 Italian Women Studied with Dna Hybridization Techniques and Morphology. Tumori Journal. 74(6). 745–749. 1 indexed citations

18.

Costanzo, Francesco Di, et al.. (1988). High-Dose Folinic Acid and 5-Fluorouracil in Advanced Colorectal Cancer. Cancer Investigation. 6(2). 133–138. 10 indexed citations

19.

Cocconi, Giorgio, Maurizio Tonato, Francesco Di Costanzo, et al.. (1986). Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.). European Journal of Cancer and Clinical Oncology. 22(7). 761–764. 30 indexed citations

20.

Liberati, Anna Marina, Francesco Di Costanzo, Franco Buzzi, et al.. (1983). 5-Fluorouracil, Vincristine and Hydroxyurea Combination Chemotherapy in Metastatic Colorectal Cancer. Tumori Journal. 69(5). 485–487. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact